07:42 AM EST, 01/22/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Wednesday said its pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in relapsed anal cancer patients. The complete response observed previously also continued beyond the 12 months initially reported.

Pelareorep-based therapy also continues to show a strong safety profile with a new chemotherapy regimen (modified Folfirinox) in pancreatic cancer patients, according to a statement.

Details from the two arms of the Goblet study will be presented through poster presentations at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium later this week.

"The posters that will be presented at the symposium later this week continue to show pelareorep's compelling potential in gastrointestinal cancers," said Chief Medical Officer Thomas Heineman.